<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="99202">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01992458</url>
  </required_header>
  <id_info>
    <org_study_id>913203</org_study_id>
    <nct_id>NCT01992458</nct_id>
  </id_info>
  <brief_title>Primary Prevention ICD French Registry</brief_title>
  <acronym>DAI-PP</acronym>
  <official_title>Observatoire Multicentrique Français Des Porteurs de Défibrillateur Automatique Implantable en Prévention Primaire (Cardiopathie Ischémique ou Cardiomyopathie Dilatée)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique Pasteur</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinique Pasteur, Toulouse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Georges Pompidou Hospital, Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Cardiologique du Nord, St Denis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nouvelles Cliniques Nantaises, Nantes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hopital Antoine Beclere, Clamart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Nancy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinique Pasteur</source>
  <oversight_info>
    <authority>France: Institutional Ethical Committee (#13.021bis)</authority>
    <authority>France: The Commission nationale de l'informatique et des libertés (#913203)</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The indication of implantable cardioverter defibrillator (ICD) therapy for primary
      prevention of sudden cardiac death has been introduced later in France than in other parts
      of the World. Overall, we aimed to assess the risk-benefit ratio of this strategy over a 10
      year period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Retrospective</study_design>
  <primary_outcome>
    <measure>Incidences of Appropriate Therapies (ATP and Shocks) and ICD-Related Complications</measure>
    <time_frame>3-year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cause-of-Death Analysis</measure>
    <time_frame>3-year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5576</enrollment>
  <condition>Evaluation of Primary Prevention ICD in Real Life</condition>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      —
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients from 12 medical centers implanted with an implantable cardioverter
        defibrillator (ICD) in the setting of primary prevention since Jan. 1, 1997, in France
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease or dilated cardiomyopathy with low ejection fraction
             implanted with an ICD in the setting of primary prevention (criteria at the
             discretion of the physician)

        Exclusion Criteria:

          -  Setting of secondary prevention

          -  Other cardiopathies such as congenital, channelopathies, valvulopathies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serge Boveda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique Pasteur</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eloi Marijon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital européen Georges Pompidou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 19, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinique Pasteur</investigator_affiliation>
    <investigator_full_name>Serge Boveda</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>implantable cardioverter defibrillator</keyword>
  <keyword>death</keyword>
  <keyword>shock</keyword>
  <keyword>mortality</keyword>
  <keyword>complication</keyword>
  <keyword>sudden death</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
